Algorithm for the use of inhaled therapies in COPD

Similar documents
Algorithm for the use of inhaled therapies in COPD Version 2 May 2017

Wirral COPD Prescribing Guidelines

Prescribing guidelines: Management of COPD in Primary Care

Co. Durham & Darlington Respiratory Network COPD Treatment Guide

If you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

Address Comorbidities

THE COPD PRESCRIBING TOOL

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD)

CHARM Guidelines for the diagnosis and

COPD Prescribing Guidelines

Respiratory Inhalers. Identification Guide Version 3

Changing Landscapes in COPD New Zealand Respiratory Conference

GMMMG COPD Formulary Inhaler Options October 2017

COPD Inhaled Therapy Prescribing Guidance

COPD Inhaled Therapy Prescribing Guidance

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma

Asthma Treatment Guideline for Adults (aged 17 and over)

3. Respiratory System

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

THEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE

GMMMG Asthma Formulary Inhaler Options August 2017

Adult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

Summary of Lothian Joint Formulary Amendments

ASTHMA TREATMENT GUIDE (ADULTS)

Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs

COPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust

Evidence Review for Prescribing Clinical Network

Include patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.

Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices

Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline

2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

Pharmacotherapy for COPD

Position within the Organisation

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Chronic Obstructive Pulmonary Disease (COPD) Guideline

VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE

COPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

Dose. Route. Units. Given. Dose. Route. Units. Given

Test Your Inhaler Knowledge

Chronic Obstructive Pulmonary Disease (COPD) Management

Chronic obstructive pulmonary disease

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18

umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline

Medical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017

Bulletin Independent prescribing information for NHS Wales

Three s Company - The role of triple therapy in chronic obstructive pulmonary

COPD: Current Medical Therapy

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)

Medicines Management of Chronic Obstructive Pulmonary Disorder (COPD)

Adjunct Associate Professor Robert Young

CHARM ASTHMA TREATMENT GUIDELINE

Guideline for the Diagnosis and Management of COPD

Chapter 3: Respiratory System (7 th Edition)

RESPIRATORY INHALERS

Design - Multicentre prospective cohort study. Setting UK Community Pharmacies within one CCG area within the UK

Presented by UIC College of Nursing

Chronic Obstructive Pulmonary Disease 1/18/2018

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

Stepping down asthma treatment guidelines

COPD 2016 What to do with all these New Inhalers?

Progress, Paediatrics and Protocols. Dr Andy Powell Dr Lesley Ayling West Hampshire CCG

Evidence Summary to support COPD formulary decision making and guideline development

Self-management plan for COPD

Chronic Obstructive Pulmonary Disease (COPD)

News on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

A multitude of devices

Not available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE

Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD.

April 10 th, Bond Street, Toronto ON, M5B 1W8

NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group

Outline. EPIC Project. February EPIC Project. Diagnosis: Spirometry. Differentiation between COPD & Asthma

Evidence Summary to support COPD formulary decision making and guideline development

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.

Drug Class Monograph

Transcription:

Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care Alliance Algorithm for the use of inhaled therapies in COPD [APC ClinDoc 007] For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics (SPC), which can be found at: http://www.medicines.org.uk/ Approval and Authorisation Approved by Job Title Date Area Prescribing Committee APC Chair May 2017 Change History Version Date Author Reason v.2.0 09/2018 unknown Updated APC Category This prescribing guideline remains open to review considering any new evidence This guideline should only be viewed online and will no longer be valid if printed off or saved locally Author - Date of production: May 2017 Job Title - Review Date March 2019 Protocol Lead - Version v 2.0

Algorithm for the use of inhaled therapies in COPD Version 2 May 2017 This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments for patients with Chronic Obstructive Pulmonary Disease. Over the last 2 years a number of new drug molecules, drug combinations, devices and branded generics have entered the market and as such it was consider appropriate to review the guidance issued in December 2015. Patients with co-existing Asthma and COPD may need to be managed differently and advice should be sought from the relevant specialist teams, if needed. Since the original guidance was issued the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has updated it s guidelines with an aim to move COPD treatment towards more individualised medicine. The ABCD assessment tool which they introduced in 2011 to determine the severity of patients COPD has been updated, the FEV1 component has been removed and severity is now exclusively informed by a patient s symptoms and exacerbation history. As the NICE guidance is now significantly out of date and does not recognise some of the new combination therapies this guidance has been reviewed using the updated GOLD classifications. The algorithm is intended for use when initiating new treatments due to disease progression and not intended to be used for switching patients from their existing treatment, unless the patient is uncontrolled or struggling to use their current treatment/device. A validated questionnaire, such as the COPD Assessment Test (CAT) should be used to assess individual patient symptoms. This algorithm recommends the use of locally preferred agents as first or second line choices. However if the patient cannot tolerate or use the preferred agents the most appropriate alternative within the recommended class(es) of drug should be prescribed. Key points to consider for all patients at all stages: Offer referral to a smoking cessation service to any person with Respiratory Disease, including COPD, who continues to smoke. Offer the pneumococcal vaccination and annual influenza vaccination as recommended by NICE. Refer to Pulmonary Rehabilitation especially if the MRC grade is 3 or above. Check inhaler technique with every device used, at every opportunity. If the patient is using a metered dose inhaler (MDI), treatment is much more effective if used with a spacer device, especially in exacerbations. Ensure every patient with COPD has a spacer to use if they use an MDI and knows how to use it. All new inhaler treatments should be assessed for effect on symptoms after a trial period (e.g. using CAT scores) and treatment should be withdrawn if no benefit is being demonstrated. Before stepping up therapy explore reasons for treatment failure. Check the PMR for ordering frequencies and confirm expected usage vs actual usage with the patient. Inhaler technique Poor inhaler technique is a very common cause of treatment failure. All clinicians involved in the management of patients with COPD should ensure that they know the correct inhaler technique for any device that their patients are using. It is important to ensure that patients are regularly asked to demonstrate how they use their different devices and that the clinician is able to correct the technique as appropriate. This is especially important when assessing if a treatment has been ineffective.

PrescQIPP have produced videos that demonstrate good inhaler technique for all the devices currently on the market, these can be accessed using the link below: https://www.prescqipp.info/respiratory#inhaler-technique-assessment-view-videos-and-implementationguides If a patient is unable to use a particular device then an alternative option from the algorithm, where possible, should be prescribed. Patients should not have their therapy stepped up before they have tried alternative devices that contain medications from the same class, unless the severity of their disease has worsened. There are a number of devices available to support improvements in inhaler technique, In-check DIAL for clinicians and 2Tone Trainer for patients. These devices are not available on the NHS. The MRC Breathlessness Scale Grade of dyspnoea Description 1 Not troubled by breathlessness except on strenuous exercise 2 Shortness of breath when hurrying on the level or walking up a slight hill 3 Walks slower than most people on the level, stops after a mile or so, or stops after 15 minutes walking at own pace. 4 Stops for breath after walking about 100m or after a few minutes on the level 5 Too breathless to leave the house or breathless when dressing or undressing CAT Score CAT Test Form.pdf *Tiotropium dry powder inhalers The two products currently available on the market, Braltus Zonda and Spiriva Handihaler have the same delivered dose of 10mcg. No dose adjustment is required and these products are interchangeable.

Algorithm for the use of inhaled therapies in COPD using a flow chart format Patients with co-existing Asthma and COPD may need to be managed differently. This algorithm is intended for the management of patients with pure COPD only. Mild Few symptoms CAT <10 and MRC 1-2 and/or 1 exacerbation and no hospital admissions in 12 months Short Acting Beta Agonist (SABA) or Short Acting Antimuscarinic when required. Salbutamol 100mcg/dose (MDI preferred, with a spacer for greater effectiveness) TWO puffs when required up to four times a day Alternative Option: Easyhaler Salbutamol 100mcg/actuation (dry powder) TWO puffs when required up to four times a day Evaluate the effect of treatment Continue, stop or try an alternative class of bronchodilator. Where a patient is using their SABA more than 4 times a day, treatment should progress to the next stage or advice should be sought from the specialist teams. Moderate Increasing symptoms CAT 10 and MRC 3 or 2 exacerbation per year or 1 hospital admission in 12 months Increasing severity Regular Long Acting Antimuscarinic Agent (LAMA. If the patient experiences no response to the first agent after 4 weeks try an alternative LAMA before trialling a LABA alone. 1 st line: Tiotropium 10mcg * OR Tiotropium 2.5mcg Incruse Ellipta (Umeclidinium 55mcg) 1 inhalation once daily 2 inhalations once daily 1 inhalation daily Alternative option where a LAMA is unsuitable (side effects, no benefit or contraindicated): Offer Long Acting Beta 2 Agonist (LABA). Continue SABA prn. Easyhaler Formoterol 12mcg 12mg daily or twice daily If there has been some response to a single agent LAMA / LABA but the patient is still symptomatic or continues to exacerbate: Offer a LAMA + LABA combination. Continue SABA prn. Anoro Ellipta (Umeclidinium 55mcg and Vilanterol 22mcg)) ONE inhalation once daily Spiolto Respimat (Tiotropium 2.5mcg and Olodaterol 2.5mcg) Two puffs once daily Severe and very severe Frequent symptoms CAT 10 and mmrc 3 and 2 exacerbation per year or 1 hospital admission in 12 months If all other treatment options have been tried (including pulmonary rehab) and the patient is still symptomatic and/or exacerbating frequently: Offer Inhaled Corticosteroid/LABA + LAMA (this should be the most cost effective single agent LAMA). Continue SABA prn. Fostair 100/6 MDI or NEXThaler (Beclometasone 100mcg and Formoterol 6mcg) Two puffs twice daily (The patient should have a spacer with the MDI device for greater effectiveness) OR Relvar Ellipta 92micrograms/22 micrograms (Fluticasone fuorate 92mcg and Vilanterol 22mcg) ONE inhalation once daily Be aware of the potential to develop side effects (including non-fatal pneumonia) in people with COPD treated with ICS and be prepared to discuss this with patients. Note this algorithm lists the locally preferred treatment options. However, if the patient cannot tolerate or use the listed inhaler device, the most appropriate alternative within the recommended class(es) of drugs should be prescribed. Version 2 May 2017 Expiry March 2019

Version 2 May 2017 Group and the Algorithm for use of inhaled therapies in COPD produced by the Southwark and Lambeth Clinical Commissioning Groups. INCREASING SYMPTOMS START Less Symptoms (CAT < 10 & MRC 1-2) More Symptoms (CAT 10 & MRC 3) LABA option where a LAMA is unsuitable (side effects, no benefit or contraindicated): Easyhaler Formoterol 12mcg 12mg daily or twice daily Alternative Options: Easyhaler Salbutamol 100mcg/actuation (dry powder) TWO puffs when required up to four times a day 1 st line: Salbutamol 100mcg/dose TWO puffs when required up to four times a day (MDI preferred, with a spacer) 1 st line LAMA: Tiotropium 10mcg* ONE inhalation once daily OR Tiotropium 2.5mcg TWO inhalations once daily Incruse Ellipta (Umeclidinium 55mcg) ONE inhalation daily SABA or SAMA when required. LAMA or LABA If the patient experiences no response to the first agent after 4 weeks try a second LAMA before trialling a LABA alone. INCREASING EXACERBATIONS OR HOSPITAL ADMISSIONS LOW RISK Exacerbation History 1 exacerbation and no hospital admissions in 12 months Evaluate the effect of treatment If there has been some response to a single agent but the patient has persistent symptoms offer a LAMA +LABA combination. Continue SABA prn Continue, stop or try alternative class of bronchodilator. (Where a patient is using their SABA more than 4 times a day, treatment should progress to the next stage or advice should be sought from the specialist teams) LAMA+LABA - Options Anoro Ellipta (Umeclidinium 55mcg and Vilanterol 22mcg)) ONE inhalation once daily Spiolto Respimat (Tiotropium 2.5mcg and Olodaterol 2.5mcg) Two puffs once daily GOLD Category A (Low symptoms and Low exacerbations) GOLD Category B (High symptoms and Low exacerbations) HIGH RISK Exacerbation History 2 exacerbations or 1 hospital admissions in 12 months Incruse Ellipta (Umeclidinium 55mcg) ONE inhalation daily Be aware of the potential to develop side effects (including non-fatal pneumonia) in people with COPD treated with ICS and be prepared to discuss this with patients. If there has been some response to a single agent LAMA but the patient has further exacerbations offer a LAMA +LABA combination. Continue SABA prn. LAMA 1 st line: Tiotropium 10mcg* ONE inhalation once daily OR Tiotropium 2.5mcg TWO inhalations once daily Plus the most cost effective single agent LAMA Relvar Ellipta 92micrograms/22 micrograms (Fluticasone fuorate 92mcg and Vilanterol 22mcg) ONE inhalation daily. Fostair 100/6 MDI or NEXThaler (Beclometasone 100mcg and Formoterol 6mcg) TWO puffs twice daily. (The patient should have a spacer with the MDI device for greater effectiveness) LAMA+LABA Options Continue SABA prn. Anoro Ellipta (Umeclidinium 55mcg and Vilanterol 22mcg)) ONE inhalation once daily Spiolto Respimat (Tiotropium 2.5mcg and Olodaterol 2.5mcg) Two puffs once daily ICS/LABA + LAMA - Options If all other treatment options have been tried (including pulmonary rehab) and the patient is still symptomatic and exacerbating frequently, offer an ICS/LABA combo plus LAMA. Continue SABA prn. GOLD Category C (Low symptoms and High exacerbations) GOLD Category D (High symptoms and High exacerbations) Patients with co-existing Asthma and COPD may need to be managed differently. This algorithm is intended for the management of patients with pure COPD only. Algorithm for the use of inhaled therapies in COPD using the GOLD Guidelines format

Group and the Algorithm for use of inhaled therapies in COPD produced by the Southwark and Lambeth Clinical Commissioning Groups. INCREASING SYMPTOMS LABA option where a LAMA is unsuitable Easyhaler Formoterol 12mcg 12mg daily or twice daily Alternative Options: Easyhaler Salbutamol 100mcg/actuation (dry powder) TWO puffs when required up to four times a day Incruse Ellipta (Umeclidinium 55mcg) ONE inhalation daily LAMA or LABA 1 st line LAMA: Tiotropium 10mcg*- ONE inhalation once daily Tiotropium 2.5mcg TWO inhalations once daily INCREASING EXACERBATIONS OR HOSPITAL ADMISSIONS INCREASING NUMBEOF EXACERBATIONS 1 st line: Salbutamol 100mcg/dose TWO puffs when required up to four times a day (MDI preferred, with a spacer) SABA or SAMA when required. LAMA+LABA - Options Anoro Ellipta (Umeclidinium 55mcg and Vilanterol 22mcg)) ONE inhalation once daily Spiolto Respimat (Tiotropium 2.5mcg and Olodaterol 2.5mcg) Two puffs once daily GOLD Category A (Low symptoms and Low exacerbations) GOLD Category B (High symptoms and Low exacerbations) Incruse Ellipta (Umeclidinium 55mcg ) - ONE inhalation daily Plus the most cost effective single agent LAMA 1 st line: Tiotropium 10mcg* ONE inhalation once daily OR Tiotropium 2.5mcg TWO inhalations once daily Relvar Ellipta 92micrograms/22 micrograms (Fluticasone fuorate 92mcg and Vilanterol 22mcg) ONE inhalation daily. LAMA Spiolto Respimat (Tiotropium 2.5mcg and Olodaterol 2.5mcg) Two puffs once daily Fostair 100/6 MDI or NEXThaler (Beclometasone 100mcg and Formoterol 6mcg) TWO puffs twice daily. (With spacer) LAMA+LABA Options. Continue SABA prn. Anoro Ellipta (Umeclidinium 55mcg and Vilanterol 22mcg)) ONE inhalation once daily ICS/LABA + LAMA Options. Continue SABA prn. GOLD Category C (Low symptoms and High exacerbations) GOLD Category D (High symptoms and High exacerbations) To be used in conjunction with the full algorithm Preferred inhaled therapies in COPD using the GOLD Guidelines format